Months after bursting into the bispecific scene out of nowhere, Janux follows the Merck hype to an IPO
Hot off of a $1 billion deal with Merck signed in December, Janux Therapeutics has been on a tear with virtually back-to-back financing rounds …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
